Clinical Trial Detail

NCT ID NCT01495988
Title Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Melanoma Research Foundation Breakthrough Consortium
Indications

melanoma

Therapies

Bevacizumab

Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST